Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Cell Therapy in Cardiology: Conference Begins in NYC Tomorrow

Daily Dose Newsroom Index

Top

Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter

Tuesday

Jan242012

Cell Therapy in Cardiology: Conference Begins in NYC Tomorrow

DDE Editor

Just a reminder that tomorrow through Friday a very important conference in NYC takes place: The Conference on Cell Therapy for Cardiovascular Disease.

Web site: http://celltherapy.crf.org/conference/overview.html

This is an off-wall street conference that is focused on reaching the medical community: Clinicians and clinical investigators, interventional cardiologists, noninvasive cardiologists, cardiac surgeons, research associates, basic science investigators (cell and molecular biologists), hospital administrators, program directors, legislators, and regulatory agency personnel to name a few. We will be attending.

A few key panels to be aware of:

Wednesday: Industry Session I. Focus on Acute Injury Technologies: 4:30 pm - 5:30 pm. The participants include Linda Marban, Alexander M Milstein, Andrew Pecora (NeoStem CMO), Kai Pinkernell, Anthony Ting, Christine Wallrapp
Thursday: Acute Injury: STEMI and NSTEMI, 8:45 am - 10:15 am. Moderators: Timothy D. Henry, Andreas M. Zeiher. Participants: Henricus J. Duckers, Raj Makkar, Marc S. Penn, Arshed A. Quyyumi (PI in NeoStem’ s Amorcyte trial) , Warren Sherman, Wojciech Wojakowski. We note that Dr. Zeiher is a moderator. Dr Zeiher is concerned one of the most prominent thought leaders in cell therapy and cardiology.
Thursday 10:45-12:15: CLI/CMI. Moderators: Douglas W. Losordo, Amit Patel. Discussants: Todd J. Brinton, Timothy D. Henry, Thomas F. O'Donnell, Emerson C. Perin, Christof Stamm, Gustav Steinhoff

On this panel we note the presence of Doug Losordo who is also one of the most respected key opinion leaders in cell therapy and is also a pioneer on CD34+ cells and cardiology. Dr. Losordo is the PI in Baxter's CD34+ trial. NeoStem also is running a CD 34+ trial.

Trial 1: CD34+ Cells for Refractory Angina: ACT 34 CMI Update and Phase 3 Study Design. Timothy D. Henry
Trial 2: Adipose-Derived Cells for Chronic Ischemia: The PRECISE Trial, Emerson C. Perin
Trial 3: Update on Standardization of CD133 Intramyocardial BMSC for Intramyocardial Delivery, Gustav Steinhoff
Trial 4: BMAC for CLI: A Phase III Trial, Thomas F. O'Donnell
Trial 5: Placenta-Derived Cells for CLI, Christof Stamm

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

Post a New Comment

Enter your information below to add a new comment.

My response is on my own website »

Author:

Author Email (optional):

Author URL (optional):

Post:

↓ | ↑

Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

Copyright by Daily Dose Equities. All rights reserved. This website contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation that any of the securities mentioned herein are appropriate for any specific individual circumstances and does not guarantee that future results or performance will match those predicted to occur. Although every effort is made to ensure the accuracy and completeness of the information on this website by using reliable data sources such as SEC filings and press releases, no guarantees are made in this regard as it has not been reviewed or certified by an independent auditor and may also include the opinions and future projections of the author. The contributing authors on this website are not chartered financial analysts, registered investment advisors or broker/dealers, and do not provide individual investment advice. The information provided by the writers on this website is for informational purposes only and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The information appearing on this website, blog, and related publications has not been reviewed or endorsed by any of the companies mentioned and should not be regarded as offical corporate news, publications, or shareholder communications. Film Annex Capital Partners, LLC (FACP) is the owner of this website and they provide strategic advisory, social media, and marketing services to emerging-growth companies. A number of the companies displayed on this site may be current or previous clients of FACP. In most instances, FACP has received fees for services for the creation, preparation and distribution of materials featured on this site, which are paid for in cash and/or stock, by the featured company ("client"). More detailed disclosure regarding fees paid is available upon request. FACP is not a broker/dealer or registered investment advisor. Information contained throughout this site is not an offer to buy or sell securities. Information presented on this site is solely for informative purposes, and is not intended, nor should they be construed, as investment advice. The information provided including news, blogs, corporate profiles, and other material is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. The companies featured on this site are typically development-stage and investment in such securities is considered highly speculative and carries a high degree of risk. Complete loss of capital is a distinct possibility. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org. Opinions stated herein may be solely FACP or the indicated source's, and not necessarily those of the featured Company. Officers, directors, and employees of FACP and financial analysts mentioned, and/or members of their families, may hold a position and may, from time to time, trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. 2010-12 Film Annex Capital Partners, LLC. All rights reserved.